C alcific aortic valve sclerosis (CAVS) causes profound morbidity in our increasingly dysmetabolic and aging citizenry. 1 Two to five percent of our elderly population will require aortic valve replacement surgery to mitigate risk of death due to severe CAVS. Once considered only a passive process of dead and dying cells, arteriosclerotic calcification, including CAVS, has emerged as an actively regulated form of mineralized tissue metabolism. 1 Preclinical and epidemiological studies reveal that aging; tobacco use; renal failure; bicuspid aortic valve; and the features of metabolic syndrome, hypertension, worsening glycemic control, hypertriglyceridemia, low high-density lipoprotein cholesterol, and obesity, 2 are cumulative risk factors for arteriosclerotic valve calcification. 1 Although hypercholesterolemia certainly contributes to risk of arteriosclerotic disease, targeting cholesterol via lipidlowering statin therapy is insufficient to fully mitigate disease progression. 1 although the molecular fingerprints of active osteogenesis are uniformly present even when amorphous calcium phosphate deposits predominate. 1, 4 Currently no medical therapies exist for preventing or treating CAVS, and our capacity to identify those at greatest risk for clinical progression is limited. 1 In the Japanese Aortic Stenosis Study (JASS), although warfarin use portended worsening disease, treatment of hypertension with angiotensin receptor blockade was associated with attenuated risk of CAVS progression. 5 Interestingly, emerging data suggest that angiotensin receptor blockades exert beneficial actions in cardiac valve biology in part via inhibition of transforming growth factor (TGF)-β signaling cascades. 6, 7 See accompanying article on page 1924
In culture, TGF-β1 clearly promotes aortic valve interstitial cell calcification, 8 with responses dependent on the stiffness of the extracellular matrix. 9 However, the contributions of TGF-β1 signaling to CAVS have not been fully examined in vivo nor has the precise cellular source of TGF-β1 important to valve pathobiology been established. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Wang et al 10 begin to address these important questions. Implementing the Reversa lowdensity lipoprotein receptor−/− mouse model of vascular disease, 11 first validated in CAVS by Miller et al, 12 the authors demonstrate that diet-induced hypercholesterolemia results in valve thickening, worsening aortic valve stenosis, increased wall shear stress (WSS; determined by echocardiographic measurement of valve leaflet separation and Doppler velocimetry), and elevated circulating TGF-β1 levels for a 12-month period. Reversing hypercholesterolemia after 6 months of dyslipidemia attenuates the severity of CAVS observed at 12 months, reflected in reductions in the rate of aortic stenosis and concomitant increases in transvalvular velocity, WSS, and plasma TGF-β1. 10 In those animals with progressive valvular disease, a modest but significant positive relationship was observed between WSS and total circulating TGF-β1 levels, with a strong trend for correlation exhibited at 12 months between circulating TGF-β1 levels and the extent of aortic valve fibrosis by histological scoring (r=0.78, P=0.08). More importantly, surgical introduction of an ascending aortic constriction (AAC) in wild-type mice, an experimental mimetic of aortic valve stenosis, also increased WSS and circulating TGF-β1 levels in the absence of hypercholesterolemia. The source of TGF-β1 was firmly established to be the platelet in the AAC model; conditional deletion of TGF-β1 in the megakaryocyte lineage (PF4-Cre;TGF-β1(fl/fl) mice) markedly reduced time-dependent increases in total plasma TGF-β1 following AAC. 10 Thus, the relationship observed between total plasma TGF-β1 levels and WSS in wild-type mice was no longer significant in PF4-Cre;TGF-β1(fl/fl) mice. Importantly, bioactive platelet-derived TGF-β1 was responsible for driving Smad2/3 and ERK phosphorylation in response to AAC in both circulating leukocytes and mesenchymal cells of the ascending aorta, and these same signaling responses were phenocopied by diet-induced aortic valve disease, WSS, and plasma TGF-β1 upregulation in the Reversa mouse model. 10 Ex vivo, stirring-induced shear of whole blood was shown to increase leukocyte Smad2/3 and ERK phosphorylation via mechanisms inhibited by neutralizing TGF-β1 antibody. Thus, platelet-derived TGF-β1 is released and signals in response to elevated aortic shear stress, activating prosclerotic signaling cascades in the arterial vasculature. 10 Why is this article so intriguing? First, the storage and release of platelet-derived TGF-β1 has significant implications vis-á-vis the emerging bone-vascular axis and the endocrine regulation of arteriosclerosis. 13 By mobilizing and recruiting mesenchymal progenitors capable of directing robust collagen deposition and matrix mineralization, TGF-β1 signaling coordinates normal bone turnover and fracture repair. 14 Wan et al 15 recently identified that with tissue injury, increases in circulating TGF-β1 mobilize and recruit bone marrow-derived mesenchymal stem cells (Sca1+CD29+CD11B-CD45-) to sites vascular remodeling, including mechanically initiated neointima formation. Therefore, by analogy, increases in WSS that promote platelet-derived TGF-β release are posited to increase circulating levels of mesenchymal stem cells capable of contributing to prosclerotic vascular responses including CAVS. Moving forward, it will be important to examine whether circulating mesenchymal stem cells are increased in response to AAC and are recruited only to that site of vascular injury or potentially populate other vascular venues with disturbed flow and dependent on platelet-derived TGF-β1. Second, this study once again points to the limitations of targeting only cholesterol in CAVS, even though lipoprotein metabolism is one critically important component of disease initiation. 1 Once valve hemodynamics are perturbed in CAVS, a vicious feed-forward cycle arising from increased WSS may continue to condition the dysmetabolic milieu with circulating TGF-β1 (see Figure) . It should be noted that Smad and noncanonical (ERK [extracellular signal-regulated kinase]) pathway activation persisted in Reversa mice; pharmacokinetic-pharmacodynamic relationships between platelet-derived TGF-β1 release and arteriosclerotic disease remain to be established. Independent of whether TGF-β1 functions by paracrine vascular actions or via mesenchymal stem cell mobilization, the administration of TGF-β1 neutralizing antibody is predicted to help mitigate CAVS disease progression, although this remains to be directly tested. Finally, this study suggests that other platelet-derived molecules such as platelet-derived growth factor 16 and Dkk1, 17 the latter participating in arteriosclerotic responses via the Smad-dependent endothelial-mesenchymal transition, 18 will be relevant to CAVS biology. Moreover, in addition to affording useful plasma biomarkers predictive of CAVS progression, targeted inhibition of TGF-β1 and other prosclerotic platelet products may represent effective strategy for mitigating disease in those individuals at greatest clinical risk. Indeed, fresolimumab, a monoclonal antibody neutralizing all forms of TGF-β and under evaluation for treatment of focal segmental glomerulosclerosis 19 and advanced melanoma, 20 might impact CAVS progression in those individuals with high plasma TGF-β1 or elevated leukocyte Smad activation. Of note, circulating levels of Dkk1 are increased in patients with severe CAVS and decrease following surgical aortic valve replacement. 21 Intriguingly, Dkk1 levels apparently do not change following transcatheter aortic implantation 21 ; whether other plateletderived signals including TGF-β1 are differentially impacted by surgical intervention remains to be assessed, and the clinical impact, if any, on arteriosclerotic disease progression in other vascular venues remains to be determined. All in all, the seminal work by Wang et al 10 provides us with an enlightened view of CAVS biology, offering new hope for diagnostic and therapeutic intervention in patients afflicted with arteriosclerotic valve and vascular disease.
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